Compugen Ltd. (CGEN)

Market Cap	173.69M
Revenue (ttm)	33.46M
Net Income (ttm)	-18.75M
Shares Out	89.53M
EPS (ttm)	-0.21
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	191,753
Open	1.890
Previous Close	1.900
Day's Range	1.855 - 1.945
52-Week Range	0.530 - 3.030
Beta	2.68
Analysts	Strong Buy
Price Target	7.25 (+274.68%)
Earnings Date	May 13, 2024

About CGEN

Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I monotherapy clinical study in patients with advanced malignancies through sequential dose escalations; Bapotulimab, a therapeutic...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Aug 11, 2000
• Employees: 68
• Stock Exchange: NASDAQ
• Ticker Symbol: CGEN

Financial Performance

In 2023, Compugen's revenue was $33.46 million, an increase of 346.12% compared to the previous year's $7.50 million. Losses were -$18.75 million, -44.34% less than in 2022.

Analyst Forecast

According to 4 analysts, the average rating for CGEN stock is "Strong Buy." The 12-month stock price forecast is $7.25, which is an increase of 274.68% from the latest price.

Price Target

$7.25

(274.68% upside)

Analyst Consensus: Strong Buy